#

Small caps

: 1220
The company will be a subcontractor for the third time for this program / Photo: Facebook/Sidus Space
Small Caps·
Sidus Space secures $2 million contract for U.S. Navy program
Gryphon Digital Mining describes itself as a green miner / Photo: Shutterstock
Small Caps·
Low-cost power acquisition expected to add $1 million in annual revenue for Bitcoin miner Gryphon
Investors are snapping up shares of monkeypox test makers as the virus spreads / Photo: REUTERS/Dado Ruvic
Small Caps·
Shares of small diagnostics companies soar amid spread of monkeypox
Lexaria uses its technology to improve existing drugs / Photo: lexariabioscience.com
Small Caps·
Lexaria on track to reduce production costs for Novo Nordisk’s diabetes drug
The growth in GeoVax stock is partly due to rival SIGA Technologies reporting disappointing trial results for its own monkeypox treatment / Photo: Shutterstock
Small Caps·
Shares of monkeypox treatment maker GeoVax surge 50% amid news flow
ACM Research is a rare small-cap stock with high growth potential and solid profitability, according to the Motley Fool / Photo: ACM Research
Small Caps·
The Motley Fool spotlights three small caps to buy ahead of expected Fed rate cuts
Sidus Space benefitted from investor interest in the satellite connectivity space following AST SpaceMobiles upbeat earnings announcement / Photo: Facebook/Sidus.space
Small Caps·
Sidus Space stock soars on positive industry news
DeFi also upgraded its full-year guidance / Photo: Reuters/Florence Lo
Small Caps·
Shares of fintech company DeFi Technologies jump after best quarter ever
Well provides medical services in the U.S. and Canada / Photo: Shutterstock
Small Caps·
Quotes on Canadian clinic owner Well rise on record revenue
Legendary small-cap investor Chuck Royce is retiring / Photo: royceinvest.com
Small Caps·
How to invest in small caps: Five tips from Wall Street legend Chuck Royce
Ideanomics stock saw a brief rebound on Tuesday / Photo: facebook.com/ideanomicshq
Small Caps·
EV company Ideanomics resumes losses in wake of fraud settlement
Zacks thinks BioStem stock should almost double from current levels /Photo: Linkedin/Biostem-technologies
Small Caps·
Zacks spotlights stock of perinatal-tissue therapy developer as undervalued
Load more